Published in Hepatitis Weekly, November 25th, 2002
This represents the final regulatory step before this first pathogen inactivation technology for platelets is available in Europe.
The Intercept Blood System is designed to protect patients by reducing the risk of transfusion-transmitted diseases through blood transfusions by inactivating certain known and potential emerging pathogens in blood components.
Application of this technology to platelets is the first to be approved and clinical trials are underway for use...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.